Disc Medicine, Inc. has recently filed a Form 144, which indicates a planned sale of shares by one of its shareholders. The filing, dated October 19, 2026, reveals that Atlas Venture Fund XII, L.P. intends to sell 115 shares of common stock.
This event is significant for Disc Medicine as it highlights ongoing shareholder activity and may reflect broader trends in the pharmaceutical preparations sector. The sale of shares can impact investor sentiment and liquidity, influencing how the market perceives the company's financial health and growth potential.
Background on Disc Medicine
Disc Medicine, Inc. operates in the pharmaceutical preparations industry, classified under the SIC code 2834. The company is listed on the Nasdaq under the ticker symbol IRON. As a large accelerated filer, Disc Medicine is subject to rigorous reporting and compliance standards.
What the Filing Says
The Form 144 filing indicates that the shares to be sold were acquired through a private placement on May 1, 2020. The aggregate market value of the shares being sold is approximately $6,536.60. The filing states, "See attached Table II for sales of securities over the last three months." This suggests that there may be additional sales reported in the accompanying documentation.
Impact
This filing may affect various stakeholders, including current and potential investors, as it provides insight into shareholder actions and the liquidity of Disc Medicine's stock. The pharmaceutical preparations sector is highly competitive, and movements by significant shareholders can influence market perceptions and investment strategies.
What's Next
The filing does not specify what happens next regarding the sale of these shares or any further actions by the company or its shareholders.
Source: SEC Accession Number 0001628280-26-066324